And there was no excuse for that infomercial in front of the White House.

The president has suggested he’d override his own regulators to rush out a coronavirus vaccine. Can ethically dubious drug companies be trusted to pump the brakes?

The emergency use authorization will make plasma and immunology research much harder—not ideal during a pandemic.

The race for a cure has put a spotlight on corporate control over medical research. Under a Democratic administration, it doesn’t have to be that way.

Platform vaccines for the coronavirus will take longer than the president thinks. But if we invest now, they could prevent pandemics in the future.

In the dangerous and secretive world of Phase I clinical trials, black men bear the greatest risks.

Why we can't leave pandemic prevention to Big Pharma

The derangements of our current era could threaten the rock-solid legal precedents that provide states with the right to act in the interests of public health.

Privatizing lifesaving technology like vaccines and clean energy is bad for both the coronavirus and the climate crisis.

A health care system designed to rake profits for an elite few is ill-suited to carrying out a nationwide herd immunity project.

The U.S. was once at the cutting edge of pandemic prevention. Then Big Pharma took over.

Global warming could unearth ancient microbes. Will we be as unprepared as we were for the coronavirus?

Competition among private medical interests is impeding the race for the cure.

After bungling containment, the Trump administration hopes for a fast-tracked fix. But compressing trials comes with its own hazards.

New York and Washington allow parents to refuse vaccinations for non-medical reasons. Both states are experiencing major measles outbreaks. This is not a coincidence.

An interview with journalist Meredith Wadman.